Slide 1: Contrafect Corporate Presentation May 2022
Contrafect Molecular treatments for infectious disease Corporate presentation may 2022 NASDAQ: CFRX
Slide 2: Forward Looking Statements
Forward Looking Statements This presentationcontains,andourofficers andrepresentatives mayfrom time to timemake,“forward-lookingstatements”withinthe meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,”
Slide 3: About ContraFect
About ContraFect ContraFect is a late clinical stage biotechnology company leading the development of direct lytic agents (DLAs), which include lysins and amurin peptides, as new medical modalities for the treatment of lif threatening and antibiot resistant infections
Slide 4: Senior Leadership
Senior LeadershipContrafect Roger Pomerantz, MD, FACP – CEO Cara Cassino, MD, FCCP – CMO & EVP, R&D Michael Messinger – CFO Natalie Bogdanos – GC, Secretary & DPO
Slide 5: Board and leadership backgrounds
Former Chairman and EVP & CCO, Real Endpoints Former CSO, CEO of Celgene Former Associate CMO, CVS Health Pharmasset Former VP, Clinical Innovation, Medco Steven C. Gilman, PhD – Vice Chair Cary Sucoff Former CEO, ContraFect President, Former EVP, R&D and CSO, Cubist Equity Source Partners
Slide 6: Antibacterial innovation sources
Sources: (1) The State of Innovation in Antibacterial Therapeutics, Bio, February 2022, excluding agents for C. difficile (2) Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis, Lancet, January 2022
Slide 7: Medical Paradigm Shifts in Standard-of-Care
Medical Paradigm Shifts in Standard-of-Care PRIOR TREATMENT NEW TREATMENT Anti-Infectives antibiotics superiority mortality benefits positive health economics microbiome direct lytic agents cancer chemotherapy immunotherapies congenital disorders no treatments available gene therapies
Slide 8: Product Candidate Portfolio in Perspective
Product Candidate Portfolio in Perspective LEADING THE DEVELOPMENT OF DLAs AS NEW MEDICAL MODALITIES Engineered Lysins Exebacase Amuri Peptides We have engineered lysins which permeate Ongoing Phase 3 superiority study comparing to We have discovered a new class of the outer membrane and kill Gram-n
Slide 9: ContraFect Portfolio
ContraFect Portfolio Program Pathogen Discovery Preclinical Phase 1 Phase 2 Phase 3 Launch Exebacase Bacteremia, including endocarditis Fast Track Breakthrough Therapy Prosthetic joint infections (PJI) Compassionate Use MRSA bacteremia in COVID patients Expanded Access CF-296 Osteomyelitis and PJI C
Slide 10: Exebacase (CF-301)
Exebacase (cf-301) novel, first-in class, Direct lytic agent for stph aureus bacteremia, including right-sided endocarditis
Slide 11: Potential Exebacase Value Proposition
Potential Exebacase Value Proposition* Exebacase, an investigational direct lytic agent, is an entirely new treatment modality, potentially offering a superior treatment for patients with challenging MRSA infections Superior clinical responder rates at Day 14 compared to antibiotics alone for patien
Slide 12: Sources: Staph aureus bacteremia mortality
Sources: (1) Extracted from Predictors of Mortality in Staphylococcus aureus Bacteremia, van Hal, 2012 (2) Referenced in Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations and Management, Tong, 2015
Slide 13: Sources: Staph aureus bacteremia characteristics
Sources: (1) Extracted from The Center for Disease Dynamics, Economics & Policy website (2) Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study, Souli, 2019
Slide 14: Exebacase: First-in-Class Lysin Candidate
Exebacase: First-in-Class Lysin Candidate Key attributes 26 kDamodular bacterial cell wall hydrolase enzyme Highly potent against Staph aureus and unique lysis and eradication of Staph biofilms Potent synergy with broad range of anti-staphylococcal antibiotics Clinical-stage program Advancing with F
Slide 15: The DISRUPT Study
The DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) Study Single, pivotal Phase 3 trial – The path to potential registration Randomized, double-blind, placebo-controlled Compares efficacy of single IV dose of exebacaseplus standard-of-care antibiotics to standard-of-care antibiotics
Slide 16: Additional Study Design Elements of the DISRUPT Study
Additional Study Design Elements of the DISRUPT Study Secondary and exploratory endpoints: 30-day all-cause mortality in MRSA patients Clinical response at Day 14 in All Staph aureus patients Clinical response at Day 30 and Day 60 Evaluation of impact on health resource utilization: Length of time i
Slide 17: Phase 2 Design
Phase 3 Based on Phase 2 Design Primary endpoint –Clinical response at Day 14 Determined by independent, blinded Adjudication Committee Defined as “improvement/resolution of signs/symptoms, no new metastatic foci of infection or complications, and no changes in antibiotic treatment or further medica
Slide 18: Overview of Phase 2 Results
Overview of Phase 2 Results Based on Phase 3 Design Primary endpoint –Clinical response at Day 14 In defined Phase 3 primary efficacy population of MRSA bacteremia patients 82.6% response vs. 33.3% SOC alone (p=0.005) Secondary endpoint –Clinical response at Day 14 In defined Phase 3 secondary effic
Slide 19: MRSA Bacteremia Opportunity for First-Line Commercial Impact
MRSA Bacteremia Opportunity for First-Line Commercial Impact Exebacase, for the treatment of Staphylococcus aureusbloodstream infections (bacteremia), including those with right-sided infective endocarditis, when used in addition to standard-of-care anti-staphylococcal antibiotics, in adult patients
Slide 20: Prosthetic Joint Infections Opportunity
Transition From Compassionate Use to Evaluate Exebacase in PJI Study Prosthetic joint infections (PJI)(1) Annual estimated cost to US hospitals of over $1.8B in 2030(1) Estimated 40,000 infections from knee procedures and 25,000 infections from hip procedures in US by 2030 with 2-3% infection rate(1
Slide 21: Compassionate Use of Exebacase in PJI
Transition From Compassionate Use to Evaluate Exebacasein PJI Study Ongoing Compassionate Use, Hôpitalde la Croix Rousse, Lyon, France Ten patients treated with exebacase(intra-articular administration), as of YE Long-term data from initial four patients with chronic knee infections included in ECCM
Slide 22: CF-370
CF-370 combating gram-negative pathogens, including mdr and xdr strains
Slide 23: CF-370 is Advancing to Next IND
CF-370 is Advancing to Next IND Based on proprietary lysin platform First lysin engineered to bypass the outer membrane of GN bacteria and show potent activity in human blood CF-370 currently in IND-enabling activities In vitro⎼ data demonstrates hallmark features of the lysin class ⎼ Rapid, pot
Slide 24: CF-370: In Vivo Activity in Lung Infection Model
CF-370: Potent In Vivo Activity in P. aeruginosa Lung Infection Model Single dose in rabbit lung infection model 100% of animals treated with CF-370 at 3 and 10 mg/kg alone or in addition to meropenem survived vs 40% in the vehicle control CF-370 alone demonstrated reduction in bacterial densities i
Slide 25: Source: Lehoux et al., ECCMID 2020
Source: Lehoux et al., ECCMID 2020 Abstract Book Publication, Abstract No. 1679
Slide 26: CF-370: In Vivo Activity in Endocarditis Model
CF-370: Potent In Vivo Activity in P. aeruginosa Endocarditis Model Single and multiple doses in rabbit infective endocarditis model Log Kill (Log10 CFU reduction vs untreated) in all target organs Synergy was observed in all target organs (up to ≥ 2-Log kill) For kidney, spleen and lungs, CF-370 at
Slide 27: Source: Watson et al., World Microbe
Source: Watson et al., World Microbe, June 2021 and internal data
Slide 28: Amurin Peptides
Amurin peptides potential broad spectrum coverage of gram-negative pathogens
Slide 29: Amurins are Broadly Active Against GN Pathogens
Amurins are Broadly Active Against GN Pathogens Novel lytic agents Potent activity observed in human blood Potential to improve clinical response and cure rates for resistant Gram-negative infections Preclinical-stage program In vitro data demonstrates hallmark features of the lysin class ⎼ ⎼ Ra
Slide 30: EM Analysis Demonstrates Mechanism of Action
EM Analysis Demonstrates Mechanism of Action Three Step Process 20 minute treatment
Slide 31: Amurin AM1 Eradicated Stenotrophomonas maltophilia Biofilms
AmurinAM1 Eradicated Stenotrophomonas maltophilia Biofilms Performed in collaboration with Dr. Jamie Dwyer, Dept. of Nephrology (Vanderbilt) Hemodialysis catheters from patients with suspected CRBSI are shipped to ContraFect and immediately processed for treatment withAM1 ex vivo Explanted hemodialy
Slide 32: Corporate Information
ContraFect © Corporate Information
Slide 33: ContraFect Investment Highlights
ContraFectInvestment Highlights Lead lysin candidate exebacase (CF-301) is a first-in-class agent with Breakthrough Therapy and Fast Tack designations for its targeting of methicillin-resistant Staph aureus (MRSA) bacteremia Currently enrolling its pivotal Ph. 3 DISRUPT trial for lead lysin candidat
Slide 34: Anticipated 2022 Milestones
Anticipated 2022 Milestones € Complete interim futility analysis in the Phase 3 DISRUPT superiority study Initiate Phase 1b/2 study in patients with Staphylococcal prosthetic joint infections Complete enrollment for the Phase 3 DISRUPT study ContraFect Initiate Phase 1 studies, for development in HA
Slide 35: Financial Information
Financial Information ContraFect fkeyMetrics [| March3,2022 Cash and securities $42.3 million Total debt a Basic shares outstanding 39.3 million Tet CoTST oe a Cantor Louise Chen Maxim Jason McCarthy Mizuho Vamil Divan SVB Securities Roanna Ruiz BB institutional Holders I} Retail/others
Slide 36: ContraFect Molecular Treatments for Infectious Disease
ContraFect MOLECULAR TREATMENTS FOR INFECTIOUS DISEASE Differentiated, first-in-class direct lytic agents (DLAs) for life-threatening, drug-resistant infections NASDAQ: CFRX